Phase ii/iii study of intraperitoneal chemotherapy after neoadjuvant chemotherapy for ovarian cancer: ncic ctg ov.21

Por Mackay, H.J., Provencheur, D., Heywood, M., Tu, D., Eisenhauer, E.A., Oza, A.M., Meyer, R.
Publicado em 2011

A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Ma...

Por Mackay, HJ, Buckanovich, RJ, Hirte, H, Correa, R, Hoskins, P, Biagi, J, Martin, LP, Fleming, GF, Morgan, R, Wang, L, Polintan, R, Oza, AM
Publicado em 2011

Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspective

Por Oza, A.M., Castonguay, V., Tsoref, D., Diaz–Padilla, I., Karakasis, K., Mackay, H., Welch, S., Weberpals, J., Hoskins, P., Plante, M., Provencher, D., Tonkin, K., Covens, A., Ghatage, P., Gregoire, J., Hirte, H., Miller, D., Rosen, B., Maroun, J., Buyse, M., Coens, C., Brady, M.F., Stuart, G.C.E.
Publicado em 2011